Konruns(603590)2025-01-23 09:15Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between 40 million and 55 million yuan, a decrease of 63% to 73% compared to the previous year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between 30 million and 45 million yuan, representing a decline of 65% to 76% year-on-year[2]. - The total profit for 2023 was 122.73 million yuan, with a net profit attributable to shareholders of 150.45 million yuan[5]. - The company reported earnings per share of 0.96 yuan for the year 2023[5]. Impairment and Losses - The decrease in profit is primarily due to the impairment testing of goodwill related to the acquisition of Tailin Pharmaceutical International Co., Ltd., leading to increased asset impairment losses[6]. Audit and Uncertainties - The preliminary financial data for 2024 is subject to final audit and may change[8]. - There are no significant uncertainties that could affect the accuracy of this earnings forecast[7]. - The earnings forecast has not been audited by a registered accounting firm[4]. Investment Risks - The company emphasizes the importance of investors being aware of investment risks related to the preliminary financial data[8]. - The performance forecast period is from January 1, 2024, to December 31, 2024[3].